Clinical Implications of CGM in Patients with Type 2

Volume 3, Issue 10.

In this podcast, Dr. Roma Gianchandani from the University of Michigan identifies scenarios in which patients can benefit from ultralong-acting insulins and discuss the potential negatives of ultralong-acting insulins.

Leave a Reply

Your email address will not be published. Required fields are marked *